Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial (OSST trial)
Open Access
- 7 June 2014
- journal article
- research article
- Published by Elsevier BV in Journal of Hepatology
- Vol. 61 (4), 777-784
- https://doi.org/10.1016/j.jhep.2014.05.044
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patientsHepatology International, 2012
- Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or CHepatology, 2011
- Safety and efficacy of two‐step peginterferon α‐2a treatment in patients of chronic hepatitis B with acute exacerbationJournal of Viral Hepatitis, 2011
- Medication Nonadherence with Long-Term Management of Patients with Hepatitis B e antigen-Negative Chronic Hepatitis BDigestive Diseases and Sciences, 2011
- Sequential therapy with adefovir dipivoxil and pegylated Interferon Alfa-2a for HBeAg-negative patientsJournal of Viral Hepatitis, 2010
- Chronic hepatitis B: Update 2009Hepatology, 2009
- Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis BHepatology International, 2008
- Intrahepatic CD8+ T-lymphocyte response is important for therapy-induced viral clearance in chronic hepatitis B infectionJournal of Hepatology, 2005
- Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2004
- Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis BHepatology, 2004